Sermorelin

Sermorelin is GHRH(1-29)NH₂, the minimal biologically active fragment of human growth hormone releasing hormone. Unlike CJC-1295, Sermorelin does not contain DPP-IV-resistant amino acid substitutions, resulting in a shorter half-life that mirrors native GHRH kinetics. This makes it the reference standard for researchers studying physiological GHRH signaling.

Research applications include GHRH receptor pharmacology, growth hormone pulse physiology, GH/IGF-1 axis studies, comparative GHRH analog research (Sermorelin vs CJC-1295), and pituitary somatotroph biology. Sermorelin's native-like kinetics make it the standard comparator in GHRH analog studies.

Every batch of Sermorelin is synthesized using Solid-Phase Peptide Synthesis (SPPS) and purified via preparative HPLC to eliminate truncated sequences and synthesis byproducts. Final identity confirmation is performed via Electrospray Ionization Mass Spectrometry (ESI-MS), verifying exact molecular weight. Each lot ships with a Certificate of Analysis documenting purity exceeding 99%, giving researchers traceable, batch-specific verification before use in any laboratory protocol.

This product is strictly for research and laboratory use only. It is not approved by the FDA or any global regulatory body for human consumption, veterinary use, or therapeutic application. The purchaser assumes all responsibility for the proper handling, storage, and application of this compound. It must only be handled by qualified professionals in a controlled laboratory setting. By purchasing this product, you agree to abide by all local and international laws regarding the use of research chemicals.